Biotron (ASX:BIT) Asset Impairment Charge : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Biotron Asset Impairment Charge?

Biotron's Asset Impairment Charge for the six months ended in Dec. 2024 was A$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Biotron Asset Impairment Charge Historical Data

The historical data trend for Biotron's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Asset Impairment Charge Chart

Biotron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Asset Impairment Charge

Get a 7-Day Free Trial

Biotron Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Biotron Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Biotron Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Biotron's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (ASX:BIT) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

BITRF:USA

Address

56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113

Website

https://www.biotron.com.au

Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron Headlines

From GuruFocus

BlackRock Announces Fiscal Year End Change for BlackRock Multi-Sector Income Trust (BIT)

By Business Wire Business Wire • 06-01-2023

BlackRock Multi-Sector Income Trust's Dividend Analysis

By GuruFocus Research • 10-13-2023

BlackRock Multi-Sector Income Trust (BIT) Declares Monthly Dividend

By GuruFocus News • 04-02-2025